Innovative Data Featuring Nanox AI Cardiac Solution Showcased at SCCT 2024
Nanox.AI's Cardiac Solution (HealthCCSng) was featured in multiple scientific presentations at the 2024 SCCT Annual Meeting, showcasing its potential in early detection and preventive care of cardiovascular disease. Key findings include:
1. Brigham & Women's Hospital study: HealthCCSng detected Coronary Artery Calcification (CAC) in over 50% of immune-mediated inflammatory disease patients, associated with increased mortality and cardiovascular risks.
2. Corewell Health implementation: HealthCCSng analyzed 32,650 chest CT scans, identifying 3,721 new patients with medium/high CAC, a 13-fold increase from previous years.
3. Jefferson Einstein Hospital study: HealthCCSng identified 757 patients with high CAC levels, leading to 308 follow-up visits and generating up to $130,000 in revenue.
These studies demonstrate HealthCCSng's clinical and economic benefits in improving cardiovascular risk assessment and patient care.
La Soluzione Cardiaca di Nanox.AI (HealthCCSng) è stata presentata in diverse presentazioni scientifiche durante il Meeting Annuale SCCT 2024, evidenziando il suo potenziale nella rilevazione precoce e nella cura preventiva delle malattie cardiovascolari. I risultati principali includono:
1. Studio del Brigham & Women's Hospital: HealthCCSng ha rilevato la Calcificazione delle Arterie Coronarie (CAC) in oltre il 50% dei pazienti con malattie infiammatorie mediato da immunità, associata a un aumento della mortalità e dei rischi cardiovascolari.
2. Implementazione di Corewell Health: HealthCCSng ha analizzato 32.650 scansioni CT toraciche, identificando 3.721 nuovi pazienti con CAC medio/alto, un aumento di 13 volte rispetto agli anni precedenti.
3. Studio del Jefferson Einstein Hospital: HealthCCSng ha identificato 757 pazienti con alti livelli di CAC, portando a 308 visite di follow-up e generando fino a 130.000 dollari di entrate.
Questi studi dimostrano i benefici clinici ed economici di HealthCCSng nel migliorare la valutazione del rischio cardiovascolare e la cura dei pazienti.
La Solución Cardíaca de Nanox.AI (HealthCCSng) fue presentada en múltiples presentaciones científicas en la Reunión Anual de SCCT 2024, mostrando su potencial en la detección temprana y el cuidado preventivo de enfermedades cardiovasculares. Los hallazgos clave incluyen:
1. Estudio del Brigham & Women's Hospital: HealthCCSng detectó Calcificación de las Arterias Coronarias (CAC) en más del 50% de los pacientes con enfermedades inflamatorias mediadas por inmunidad, lo que está asociado con un aumento de la mortalidad y los riesgos cardiovasculares.
2. Implementación de Corewell Health: HealthCCSng analizó 32,650 escaneos de TC de tórax, identificando 3,721 nuevos pacientes con CAC medio/alto, un aumento de 13 veces en comparación con años anteriores.
3. Estudio del Jefferson Einstein Hospital: HealthCCSng identificó 757 pacientes con altos niveles de CAC, lo que resultó en 308 visitas de seguimiento y generó hasta $130,000 en ingresos.
Estos estudios demuestran los beneficios clínicos y económicos de HealthCCSng en la mejora de la evaluación del riesgo cardiovascular y la atención del paciente.
Nanox.AI의 심장 솔루션(HealthCCSng)은 2024 SCCT 연례 회의에서 여러 과학 발표에 소개되어 심혈관 질환의 조기 발견 및 예방 치료의 잠재력을 보여주었습니다. 주요 발견 사항은 다음과 같습니다:
1. 브리검 여성 병원 연구: HealthCCSng는 면역 매개 염증 질환 환자의 50% 이상에서 관상동맥 칼슘화(CAC)를 감지하였으며, 이는 사망률 증가 및 심혈관 위험과 관련이 있습니다.
2. 코어웰 헬스 구현: HealthCCSng는 32,650개의 흉부 CT 스캔을 분석하여 중간/높은 CAC를 가진 3,721명의 새로운 환자를 발견하였으며, 이는 이전 해에 비해 13배 증가한 수치입니다.
3. 제퍼슨 아인슈타인 병원 연구: HealthCCSng는 높은 CAC 레벨을 가진 757명의 환자를 확인하였으며, 이로 인해 308회의 후속 방문이 발생하였고 최대 130,000달러의 수익을 창출하였습니다.
이 연구들은 HealthCCSng가 심혈관 위험 평가와 환자 치료 개선에 있어 임상적 및 경제적 이점을 제공함을 보여줍니다.
La solution cardiaque de Nanox.AI (HealthCCSng) a été présentée lors de plusieurs présentations scientifiques lors de la réunion annuelle SCCT 2024, mettant en avant son potentiel dans la détection précoce et les soins préventifs des maladies cardiovasculaires. Les résultats clés comprennent :
1. Étude de l'hôpital Brigham & Femmes : HealthCCSng a détecté une calcification des artères coronaires (CAC) chez plus de 50 % des patients atteints de maladies inflammatoires médiées par immunité, associée à une augmentation de la mortalité et des risques cardiovasculaires.
2. Mise en œuvre de Corewell Health : HealthCCSng a analysé 32 650 scanners CT thoraciques, identifiant 3 721 nouveaux patients avec CAC moyen/élevé, soit une augmentation de 13 fois par rapport aux années précédentes.
3. Étude de l'hôpital Jefferson Einstein : HealthCCSng a identifié 757 patients avec des niveaux élevés de CAC, entraînant 308 visites de suivi et générant jusqu'à 130 000 $ de revenus.
Ces études démontrent les avantages cliniques et économiques de HealthCCSng pour améliorer l'évaluation du risque cardiovasculaire et les soins aux patients.
Die Herzlösung von Nanox.AI (HealthCCSng) wurde in mehreren wissenschaftlichen Präsentationen auf dem Jahresmeeting 2024 der SCCT vorgestellt, wobei ihr Potenzial für die Früherkennung und präventive Behandlung von Herz-Kreislauf-Erkrankungen hervorgehoben wurde. Wichtige Ergebnisse umfassen:
1. Studie des Brigham & Women's Hospital: HealthCCSng hat bei über 50% der Patienten mit immunvermittelten entzündlichen Erkrankungen eine Koronararterienverkalkung (CAC) festgestellt, die mit erhöhtem Sterberisiko und kardiovaskulären Risiken verbunden ist.
2. Implementierung durch Corewell Health: HealthCCSng hat 32.650 Brust-CT-Scans analysiert und 3.721 neue Patienten mit mittel-hoher CAC identifiziert, was eine 13-fache Zunahme gegenüber den Vorjahren darstellt.
3. Studie des Jefferson Einstein Hospitals: HealthCCSng hat 757 Patienten mit hohen CAC-Werten identifiziert, was zu 308 Folgeuntersuchungen führte und Einnahmen von bis zu 130.000 US-Dollar generierte.
Diese Studien zeigen die klinischen und wirtschaftlichen Vorteile von HealthCCSng bei der Verbesserung der kardiovaskulären Risikoabschätzung und der Patientenversorgung.
- Nanox.AI's Cardiac Solution was featured in multiple scientific presentations at SCCT 2024, validating its effectiveness
- HealthCCSng detected CAC in over 50% of IMID patients, associated with increased mortality and cardiovascular risks
- Corewell Health implementation led to a 13-fold increase in identifying patients with medium/high CAC
- Jefferson Einstein Hospital study showed HealthCCSng generated up to $130,000 in revenue from follow-up visits
- Multiple studies demonstrated HealthCCSng's potential to improve early detection and preventive care of cardiovascular disease
- None.
Insights
This news is not impactful for stock market investors. While the article presents interesting clinical data about Nanox's AI Cardiac Solution (HealthCCSng), it primarily focuses on scientific presentations at a medical conference. The information provided doesn't include financial results, regulatory updates, or other elements that would significantly impact the company's stock performance in the short term.
The studies presented demonstrate the potential clinical utility of Nanox's AI solution in identifying patients at risk for cardiovascular disease. However, these are early-stage findings that require further validation and don't directly translate to immediate revenue or market expansion for the company.
For long-term investors, this news may be seen as a positive indicator of Nanox's technology development and potential future market opportunities. However, it doesn't provide concrete financial or business metrics that would typically drive stock movements.
In a study conducted by Brigham & Women’s Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over
In a study conducted by Jefferson Einstein Hospital, Nanox.AI Cardiac Solution Flags CAD High-Risk Patients, Drives Significant Revenue
Additional data presented by Corewell Health, Massachusetts General Hospital and Rabin Medical Center
PETACH TIKVA, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox.AI Ltd., was highlighted in multiple scientific presentations at the 2024 Society of Cardiovascular Computed Tomography (SCCT) Annual Meeting.
“We are encouraged by the implementation of our AI cardiac solution at esteemed healthcare systems, along with the continued validation through real-world studies of its potential to promote early detection and preventive care of cardiovascular disease,” said Erez Meltzer, Nanox Chief Executive Officer and Acting Chairman. “We would also like to thank SCCT for the opportunity to showcase the outstanding clinical results of our AI cardiac solution.”
Findings presented at SCCT 2024 include:
Prevalence and Prognostic Implications of Incidentally Detected Coronary Artery Calcium Using Artificial Intelligence Analysis Among Individuals with Immune Mediated inflammatory Diseases
- Abstract Link (2024-A-817-SCCT)
- Lead author Brittany Weber, MD, PhD, declared as ‘Young Investigator Awards Winner’ at conference
- In a study conducted by Brigham & Women’s Hospital, HealthCCSng was used to analyze non-cardiac, non-gated chest CT scans of patients with different types of immune mediated inflammatory disease (IMID) – systemic lupus erythematosus, psoriasis, and rheumatoid arthritis – which are associated with increased risk of cardiovascular disease.
- The study demonstrates that Incidental Coronary Artery Calcification (CAC) on the CT scans of the IMID patients (identified and quantified by HealthCCSng), was found in over
50% of scanned patients and associated with all-cause mortality and adverse cardiovascular outcomes. - According to the study, Given the limitations of traditional cardiovascular risk calculators among IMID patients, this data demonstrates the potential of AI-based CAC scoring to offer better guidance for preventative therapies for that patient population.
Optimizing Preventive Cardiology: Harnessing AI for Early Detection of Coronary Artery Disease
- Abstract Link (2024-A-573-SCCT)
- Corewell Health reported that in the first full year of implementing HealthCCSng in its electronic medical records (EMR) system, HealthCCSng analyzed 32,650 chest CT scans and helped identify 3,721 new patients with medium or high CAC – a thirteen-fold increase over the 268 patients reported in the previous two years.
- Corewell also reported decreased time to treatment, increased statin prescription rate, increased patient satisfaction with the actionable data concerning their cardiac risk, and improved patient compliance in treatment.
- This observational study demonstrated that the Nanox.AI algorithm is useful in the process of identifying patients with undiagnosed Coronary Artery Disease (CAD) and that AI integrated into the EMR can positively impact population health goals.
AI Empowering Early Detection of CAD Patients for Improved Cardiac Care
- Abstract Link (2024-A-641-SCCT)
- After being installed and implemented at Jefferson Einstein Hospital, HealthCCSng helped identify 757 patients aged 30 or above with CAC levels higher than 100 Agatston units.
- Of these 757 identified patients, 179 met eligibility criteria to be automatically flagged for follow-up consultation and treatment.
- Of these 179 eligible patients, 97 returned to Jefferson Einstein for visits totaling 308 total touchpoints.
- The above-mentioned touchpoints generated up to
$130,000 in revenue for the hospital. - This analysis shows both the clinical and economic effects of implementing an AI solution (HealthCCSng, Nanox.AI) to opportunistically screen large populations.
Artificial–Intelligence-based Detection of Coronary Artery Calcium on Chest CT to Enhance Cardiovascular Risk Assessment of Individuals with Elevated Lipoprotein (a)
- Abstract Link (2024-A-820-SCCT)
- In a study conducted by Massachusetts General Hospital and Brigham & Women’s Hospital, HealthCCSng was used to analyze non-contrast chest CT scans of 260 patients who had measurements of lipoprotein a (Lp(a)), as part of clinical care.
- A statistically significant correlation was found between levels of CAC and Lp(a) – a risk factor for coronary atherosclerosis – suggesting that this approach may be used to identify at-risk patients.
- Such an approach may be used to identify higher risk individuals and screen patients for future clinical trials.
Opportunistic Screening of Coronary Artery Calcification on Non-gated Conventional CT scans Using Artificial Intelligence
- Abstract Link (2024-A-532-SCCT)
- In a study conducted by Rabin Medical Center, HealthCCSng was used to analyze non-gated, non-contrast chest CT scans of 631 patients.
- 84 clinically relevant patients were classified as having high CAC levels and invited to a dedicated outpatient preventive cardiology clinic.
- 20 patients were referred to myocardial perfusion imaging and 2 were referred for invasive coronary angiography.
- This data suggests that AI-based CAC evaluation can help identify patients who may benefit from preventive cardiology services.
- Using HealthCCSng, Rabin Medical Center was able to identify new patients with severe CAC who were previously unknown to the health system and as a result, these patients were scheduled to visit the preventive cardiology clinic.
About Nanox.AI
Nanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI’s solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI technology, Nanox.AI helps clinicians extract valuable and actionable clinical insights from routine medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit https://www.nanox.vision/ai.
About Nanox
Nanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. Nanox’s vision is to increase access, reduce costs and enhance the efficiency of routine medical imaging technology and processes, to improve early detection and treatment, which Nanox believes is key to helping people achieve better health outcomes, and, ultimately, to save lives. The Nanox ecosystem includes Nanox.ARC— a multi-source Digital Tomosynthesis system that is cost-effective and user-friendly; an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic disease (Nanox.AI); a cloud-based infrastructure (Nanox.CLOUD); and a proprietary decentralized marketplace, through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts; and a comprehensive teleradiology services platform (Nanox.MARKETPLACE). Together, Nanox’s products and services create a worldwide, innovative, and comprehensive solution that connects medical imaging solutions, from scan to diagnosis. For more information, please visit www.nanox.vision.
Contacts
Media Contact:
Ben Shannon
ICR Westwicke
NanoxPR@icrinc.com
Investor Contact:
Mike Cavanaugh
ICR Westwicke
mike.cavanaugh@westwicke.com
FAQ
What were the key findings of the Brigham & Women's Hospital study using Nanox.AI's HealthCCSng (NNOX)?
How did Corewell Health's implementation of Nanox.AI's HealthCCSng (NNOX) impact patient identification?
What were the economic benefits of implementing Nanox.AI's HealthCCSng (NNOX) at Jefferson Einstein Hospital?
How did Nanox.AI's HealthCCSng (NNOX) perform in the Massachusetts General Hospital and Brigham & Women's Hospital study?
